MDC CRISPR/Cas9 KO Plasmid (m): sc-422840
- Target species: mouse
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- MDC CRISPR/Cas9 Knockout (KO) Plasmid (m) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the MDC genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: MDC Antibody (R-19): sc-74223
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
MDC CRISPR/Cas9 KO Plasmid (m) | sc-422840 | 20 µg | $397.00 |
Overview
Ccl22 encodes the chemokine macrophage-derived chemokine (MDC), a CCR4 ligand that promotes directed migration of immune cells, particularly Th2-polarized CD4+ T cells, regulatory T cells, and other CCR4-expressing leukocytes. MDC is produced by macrophages, dendritic cells, and other stromal/immune populations in response to inflammatory cues, shaping leukocyte trafficking, antigen-driven responses, and tissue immune composition. Through chemokine receptor signaling that engages GPCR-dependent pathways such as PI3K–AKT and MAPK and modulates cytoskeletal dynamics, Ccl22 contributes to immune homeostasis and local inflammatory microenvironments. Dysregulated Ccl22/MDC signaling has been associated with altered T cell recruitment patterns relevant to allergic inflammation, autoimmunity, and tumor-immune interactions in murine models.
MDC CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Ccl22 gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Ccl22 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Ccl22 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish MDC protein expression.
This CRISPR knockout system enables efficient generation of Ccl22-deficient cell models for investigation of MDC signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting Ccl22 exon(s) critical for MDC function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple Ccl22 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by MDC CRISPR/Cas9 KO Plasmid (m) and MDC CRISPR/Cas9 KO Plasmid (m2) target distinct sites within the Ccl22 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by MDC HDR Plasmid (m) and MDC HDR Plasmid (m2) contain a puromycin resistance cassette and an RFP reporter flanked by Ccl22 homology arms to support homology-directed repair at defined Ccl22 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.